Corcept Therapeutics Cash Flow Statement
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corcept Therapeutics free cash flow
In fiscal 2025, Corcept Therapeutics generated $142.0 million of operating cash flow and spent $211,000 on capital expenditures. That left free cash flow of $141.8 million, a free-cash-flow margin of 18.6% of revenue. Free cash flow was down 27.7% from the prior year's $196.1 million.
Corcept Therapeutics returned $172.9 million to shareholders through share repurchases, equal to 122% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Corcept Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 99.65M | 141.21M | 106.14M | 101.42M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M |
| Net Income growth (YoY) | -29.43% | +33.04% | +4.66% | -9.86% | +6.13% | +12.56% | +24.89% | -41.60% | +1486.27% | — |
| Depreciation & Amortization | 1.15M | 795.00K | 1.04M | 1.26M | 1.07M | 525.00K | 703.00K | 236.00K | 106.00K | 87.00K |
| Stock-Based Compensation | 84.50M | 61.35M | 48.94M | 42.44M | 42.93M | 33.54M | 29.31M | 23.75M | 13.36M | 7.06M |
| Change in Working Capital | 13.23M | -14.64M | -4.86M | 549.00K | 337.00K | -8.18M | -7.52M | -10.46M | -1.44M | -3.51M |
| Operating Cash Flow | 142.00M | 198.29M | 126.68M | 120.32M | 167.89M | 151.97M | 136.12M | 115.67M | 60.94M | 18.39M |
| Capital Expenditures | -211.00K | -2.17M | -139.00K | -413.00K | -469.00K | -1.24M | -1.09M | -298.00K | -419.00K | -194.00K |
| Investing Cash Flow | 69.76M | -177.60M | 90.91M | -114.33M | 136.13M | -119.26M | -117.83M | -90.77M | -73.46M | -194.00K |
| Share Repurchases | -172.91M | -15.66M | 0 | 0 | — | -9.95M | -30.98M | -23.66M | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | -15.13M | -14.78M |
| Financing Cash Flow | -220.37M | -28.35M | -148.72M | -17.28M | -302.59M | 12.21M | -28.64M | -14.34M | -7.95M | -7.10M |
| Net Change in Cash | -7.17M | -7.89M | 69.22M | -11.29M | 1.43M | 44.92M | -10.36M | 10.56M | -20.47M | 11.10M |
| Free Cash Flow | 141.78M | 196.12M | 126.54M | 119.91M | 167.42M | 150.73M | 135.03M | 115.37M | 60.52M | 18.20M |
This table shows 10 annual periods of Corcept Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CORT's reporting calendar. What is a cash flow statement?